February 24, 2014

Alzheimer’s Imaging Agents: The Regulatory Horizon

“Alzheimer’s disease is probably the most underfunded disease in the U.S.,” charges Dean M. Hartley, PhD, director of science initiatives, medical and scientific relations, for the Alzheimer’s Association. And money matters. A cursory review of the history of major diseases like cancer and heart disease shows that cures are proportional to research dollars, continues Hartley. It’s not only the disproportionate funding that has Alzheimer’s stakeholders up in arms. The July 2013 draft decision by CMS to limit reimbursement for florbetapir PET to coverage with evidence development represents a potentially devastating blow to the dissemination of amyloid PET imaging. {read more here}